|Bid||7.35 x 1300|
|Ask||7.47 x 800|
|Day's Range||7.38 - 7.72|
|52 Week Range||7.13 - 11.68|
|Beta (5Y Monthly)||0.28|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 03, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.86|
CytoSorbents Corporation (NASDAQ: CTSO) a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, will report second quarter 2021 operating and financial results after the market close on August 3, 2021.
Shares of Cytosorbents Corporation (NASDAQ: CTSO) jumped 17.3% on Tuesday, spurred higher by news that the Investigational Device Exemption (IDE) request for its DrugSorb-ATR Antithrombotic Removal system has been approved by the U.S. Food and Drug Administration, allowing clinical trials of the device to move forward. Cytosorbents' DrugSorb-ATR Antithrombotic Removal device just cleared another regulatory hurdle. Exempt from certain other steps that some medical devices must go through, the company can now begin testing the device, which allows patients undergoing heart bypass surgeries to curb the amount of blood-thinning drug ticagrelor in the bloodstream during and after the procedure.
CytoSorbents Corporation (NASDAQ: CTSO) receives full FDA approval to conduct the STAR-T trial in the U.S. to support regulatory clearance of DrugSorb Antithrombotic Removal (ATR) system for intraoperative ticagrelor removal during cardiothoracic surgery. This study is being performed under the previously announced FDA Breakthrough Designation received in April 2020. STAR-T will enroll up to 120 patients, and enrollment is expected to begin soon. The study's primary endpoint will evaluate whethe